CXCL12-CXCR4 retention — the axis everyone calls the niche dependency, and the CRISPR screen that says the ligand is not required
also called SDF-1/CXCR4 axis · chemokine retention axis · CXCR4 signalling in leukaemia
Bone-marrow support cells release a chemical called CXCL12, and blood cells that carry its receptor CXCR4 are drawn to it and held in place; block the receptor and the cells wash out into the bloodstream within hours. This is the mechanism behind the drug plerixafor, and the standard explanation for why leukaemia cells in the marrow are harder to kill than ones in the blood.
The same thing, for a scientist
CXCL12 (SDF-1) binding CXCR4 is the retention and maintenance axis of the marrow niche: induced CXCR4 deletion in adults collapses the HSC pool [E1], and compartment-specific Cxcl12 deletion partitions the niche, with perivascular-stromal CXCL12 maintaining HSCs and osteoblast CXCL12 maintaining early lymphoid progenitors [E2]. In KMT2A-rearranged disease the axis is the best-characterised niche dependency: primary infant MLL-rearranged ALL is **differentially** protected by stroma relative to non-MLL-rearranged ALL, soluble stromal factors alone suffice, and CXCR4 antagonism reverses the protection (recorded in `mechanism-kmt2a-r-tissue-localization`). This entry exists to record the result that complicates that picture. A CRISPR-Cas9 cell-surface screen in syngeneic MLL-AF9 AML found CXCR4 a **top** dependency, but **Cxcr4 deletion eradicated leukaemia without impairing marrow homing**, **CXCL12 was dispensable** for leukaemia development in recipients, mutant-receptor experiments showed signalling is what is required, and loss of CXCR4 signalling caused **oxidative stress and differentiation** in vivo [E3]. In an MLL::AF9 model the protective CXCL12 comes from Prx1+ mesenchymal cells and works through redox and energy balance, with the deletion phenotype **attenuated by antioxidant therapy** [E4]. Two readings of the same axis, and the therapeutic inferences differ.
Why this is not just a restatement of the localisation entry
mechanism-kmt2a-r-tissue-localization already records that KMT2A-rearranged ALL is differentially protected by stroma and that CXCR4 antagonism reverses it, with plerixafor and POL5551 as the pharmacological handles. That entry establishes the phenomenon. This entry is about the mechanism, and specifically about a finding that entry does not carry: that in the best-controlled genetic experiment done in this genotype, the receptor is required and the ligand is not 3.
What CXCR4 deletion did in that model is worth stating precisely, because it is not what the retention model predicts. Homing to marrow was unimpaired. The leukaemia was eradicated anyway. Mutant-receptor variants showed the requirement is for signalling. And the phenotype of losing that signalling was oxidative stress and differentiation — a cell-intrinsic survival and identity requirement, not a positional one.
If that is right, then a CXCR4 antagonist in KMT2A-rearranged disease is not primarily a mobilisation agent. It is a signalling inhibitor whose effect happens to be measured by mobilisation. The two accounts predict different things: the mobilisation account predicts benefit only when the drug is timed to precede cytotoxic chemotherapy, and the signalling account predicts single-agent activity. The paediatric trial evidence (trial-poe-10-03-plerixafor-paediatric) shows robust mobilisation - a median 3.4-fold increase in circulating blasts, correlating with surface CXCR4 - with only modest clinical responses, which is the combination that ought to make anyone cautious about both accounts.
The redox reading, and the prediction it makes
The third account is metabolic and reconciles part of the conflict. Viñado and colleagues found that CXCL12 from Prx1+ mesenchymal cells (not mature osteolineage cells) maintains MLL::AF9 leukaemia stem cells by modulating energy metabolism and redox balance; Cxcl12 deletion caused ROS accumulation and DNA damage in LSCs and impaired serial transplantation, and antioxidant therapy attenuated the defect 4. Note that losing CXCR4 signalling in 3 also produced oxidative stress. Both the ligand-deletion and the receptor-deletion phenotypes converge on redox.
That gives a sharp, cheap, falsifiable prediction: a CXCR4 antagonist should lose efficacy when co-administered with an antioxidant. If it does, the axis is a redox-support axis and should be combined with oxidative stressors rather than with mobilisation-timed cytotoxics. If it does not, the retention model survives. Nobody has run it; it is written up as exp-cxcr4-antagonist-antioxidant-rescue.
| mechanism class | chemokine receptor signalling and marrow retention |
|---|---|
| ligand | CXCL12 (SDF-1) |
| receptor | CXCR4 |
| clinical status in kmt2a | no CXCR4-directed trial in KMT2A-rearranged or infant leukaemia exists; see ana-cxcr4-directed-trials-kmt2a-infant |
| literature size | CXCR4 x KMT2A PubMed intersection is 11 records; CXCL12/SDF-1 x KMT2A is 7 |
cellular sources of ligand
[
{
"source": "CAR / LEPR+ perivascular stromal cells",
"maintains": "HSCs",
"source_evidence": "E2"
},
{
"source": "endothelium",
"maintains": "HSCs, not lymphoid or myeloerythroid progenitors",
"source_evidence": "E2"
},
{
"source": "osteoblasts",
"maintains": "certain early lymphoid progenitors",
"source_evidence": "E2"
},
{
"source": "Prx1+ mesenchymal cells",
"maintains": "MLL::AF9 leukaemia stem cells via redox and energy balance",
"source_evidence": "E4"
}
]competing models
[
{
"model": "retention",
"prediction": "antagonist works only when timed to precede cytotoxic therapy",
"status": "supported by human KMT2A-r ALL stromal co-culture and xenograft data"
},
{
"model": "cell-intrinsic signalling",
"prediction": "antagonist or receptor loss has activity independent of mobilisation",
"status": "supported by CRISPR screen in murine MLL-AF9 AML; ligand dispensable"
},
{
"model": "redox support",
"prediction": "antagonist efficacy is abolished or reduced by co-administered antioxidant",
"status": "untested; written up as exp-cxcr4-antagonist-antioxidant-rescue"
}
]pharmacology
[ "plerixafor (AMD3100)", "POL5551", "motixafortide (BL-8040)", "ulocuplumab (BMS-936564)" ]
atlas refs
[
{
"label": "CXCL12-CXCR4 maintenance of the HSC pool",
"pmid": "17174120",
"title": "Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches.",
"authors": "Sugiyama T, Kohara H, Noda M, et al.",
"venue": "Immunity",
"year": 2006,
"title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
},
{
"label": "CXCR4 essential CXCL12-independently in MLL-AF9 AML",
"pmid": "32460032",
"title": "CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.",
"authors": "Ramakrishnan R, Peña-Martínez P, Agarwal P, et al.",
"venue": "Cell Rep",
"year": 2020,
"title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
}
]- CXCR4 blockade mobilises normal HSCs as reliably as leukaemic blasts - that is its licensed clinical use - so the therapeutic window depends entirely on the partner drug being more toxic to blasts than to stem cells.
- Mobilising blasts into the circulation in a disease that already presents with hyperleukocytosis risks worsening leukostasis, a recognised emergency in this population (`concept-hyperleukocytosis-emergency`).
- If the requirement is cell-intrinsic signalling rather than retention, then pharmacological antagonists that block ligand binding may not reproduce the genetic deletion phenotype at all, and the preclinical genetics would be over-promising.
- Reversing niche protection releases dormant cells into cycle; if the release is incomplete, it selects for the cells that stayed.
- Does a CXCR4 antagonist lose efficacy when given with an antioxidant? Both the ligand-deletion and the receptor-deletion phenotypes in this genotype converge on oxidative stress, so this single experiment would decide between the retention and redox models.
- Is CXCR4 required in KMT2A::AFF1 B-lymphoid disease for the same reason it is required in MLL-AF9 myeloid disease? The genetic work is entirely myeloid and the human protection data are entirely lymphoid.
- Plerixafor mobilised blasts a median 3.4-fold in children without producing much clinical benefit. Was the failure one of mobilisation biology, of the chemotherapy partner, or of the heavily pretreated population?
- If CXCR4 loss causes differentiation, does a CXCR4 antagonist combine with or duplicate the differentiation effect of a menin inhibitor in KMT2A-rearranged cells?
- E1established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper
Induced deletion of CXCR4 in adult mice severely reduces HSC numbers and increases sensitivity to myelotoxic injury without impairing expansion of more mature progenitors, and most HSCs are in contact with CXCL12-abundant reticular cells, establishing CXCL12-CXCR4 signalling as essential for maintaining the quiescent HSC pool.
Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches · Sugiyama T, Kohara H, Noda M, Nagasawa T · Immunity 2006What this evidence cannot show
Mouse, normal haematopoiesis. The experiment does not separate retention from survival signalling, which is exactly the distinction the leukaemia literature later forced. Read: abstract only.
Evidence that argues against this (1)
- In MLL-AF9 leukaemia the same receptor is essential for a different reason: Cxcr4 deletion eradicated leukaemia WITHOUT impairing homing to marrow, and CXCL12 was dispensable for leukaemia development in recipients. The requirement is for signalling, and its loss causes oxidative stress and differentiation rather than mislocalisation. Read: abstract only. Ramakrishnan R et al. 2020
- E2established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper
CXCL12 is primarily expressed by perivascular stromal cells and at lower levels by endothelial cells, osteoblasts and some haematopoietic cells; conditional deletion from endothelium depletes HSCs but not lymphoid or myeloerythroid progenitors, deletion from perivascular stromal cells depletes HSCs and certain restricted progenitors and mobilizes them into circulation, and deletion from osteoblasts depletes certain early lymphoid progenitors without depleting HSCs or myeloerythroid progenitors and without mobilizing them - HSCs occupy a perivascular niche and early lymphoid progenitors an endosteal niche.
Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches · Ding L, Morrison SJ · Nature 2013What this evidence cannot show
Mouse, normal adult marrow, CXCL12 only. 'Certain early lymphoid progenitors' is not resolved to named populations in the abstract. Nothing here is leukaemic. Read: abstract only.
Evidence that argues against this (1)
- In an MLL::AF9 leukaemia model the CXCL12 that maintains leukaemia stem cells comes from Prx1+ mesenchymal cells and explicitly NOT from mature osteolineage cells, so the source that matters for normal early lymphoid progenitors is not the source that matters for this leukaemia - at least in the myeloid model where it has been tested. Read: abstract only. Vinado AC et al. 2022
- E3strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
A CRISPR-Cas9 screen targeting cell-surface genes in a syngeneic MLL-AF9 mouse AML model identified CXCR4 as a top cell-surface regulator of AML cell growth and survival; deletion of Cxcr4 eradicated leukaemia cells in vivo WITHOUT impairing their homing to bone marrow; the ligand CXCL12 was dispensable for leukaemia development in recipient mice; expression of mutated Cxcr4 variants showed CXCR4 signalling is essential for leukaemia cells; and loss of CXCR4 signalling led to oxidative stress and differentiation in vivo.
CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia · Ramakrishnan R, Pena-Martinez P, Agarwal P, Rodriguez-Zabala M, Chapellier M, Hogberg C, Eriksson M, Yudovich D, et al. · Cell Reports 2020What this evidence cannot show
Mouse syngeneic MLL-AF9; myeloid, not the infant B-lymphoid disease where the human stromal-protection data sit. 'CXCL12 dispensable' is established via the recipient genotype and does not exclude alternative ligands, CXCL12 from transplanted cells, or ligand-independent constitutive signalling. Genetic deletion is not pharmacological antagonism: plerixafor blocks ligand binding rather than abolishing the receptor. Read: abstract only.
Evidence that argues against this (1)
- The human KMT2A-rearranged data point to a ligand-dependent, stroma-mediated protection that pharmacological CXCR4 antagonism reverses: primary infant MLL-rearranged ALL is differentially protected by stroma relative to non-MLL-rearranged ALL, protection is conferred by stroma-produced soluble factors alone, and AMD3100 markedly enhanced drug efficacy in xenograft. A genetic, murine, myeloid result showing ligand independence does not overturn that, and the two may simply be different diseases. Read: abstract only. Sison EA et al. 2013
- E4strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
In an MLL::AF9-induced AML model, CXCL12 produced by Prx1-positive mesenchymal cells but not by mature osteolineage cells maintains leukaemia stem cells by modulating energy metabolism and redox balance; deletion of Cxcl12 leads to accumulation of reactive oxygen species and DNA damage in LSCs and impairs their ability to perpetuate leukaemia in transplantation, a defect attenuated by antioxidant therapy, with data suggesting conservation in human patients.
The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells · Vinado AC, Calvo IA, Cenzano I, Olaverri D, Cocera M, San Martin-Uriz P, Romero JP, Vilas-Zornoza A, et al. · Leukemia 2022What this evidence cannot show
Mouse; Prx1-cre is a broad limb-bud mesenchymal driver. The human conservation claim is described as suggestive in the abstract. Antioxidant rescue is reported as attenuation, not abolition. Read: abstract only.
Evidence that argues against this (1)
- A CRISPR screen in the same driver found CXCL12 itself dispensable for leukaemia development in recipient mice while CXCR4 was a top dependency, so the ligand-deletion phenotype reported here is not reproduced as a requirement in that system. The field has not reconciled the two. Read: abstract only. Ramakrishnan R et al. 2020
the retention axis of the niche
CAR/LEPR+ and Prx1+ mesenchymal cells are the ligand source
- supports →Where KMT2A-rearranged leukemia physically sits — marrow niche, CNS, blood, liver/spleen and skin
supplies the mechanistic detail, and the CXCL12-independent counter-result, behind the niche dependency recorded there
CXCR4 is a top CRISPR dependency in murine MLL-AF9 AML, independent of CXCL12
tested CXCR4 blockade as chemosensitisation; target engaged (3.4-fold blast mobilization) with modest clinical benefit
registry sweep: no CXCR4-directed trial exists in KMT2A-rearranged or infant leukaemia
distinguishes the redox model from the retention model of CXCR4 dependence
CXCR4 blockade mobilises normal HSCs; that is its licensed use
the ligand half of the axis this mechanism is named after
the receptor half of the axis this mechanism is named after
bounds the mechanism's untested pharmacology